209 related articles for article (PubMed ID: 35116856)
1. Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy.
Guo G; Chen X; Cai X; Chen Y; Wang H; Fan L; Bai L; Qiu H; Zhang B
Transl Cancer Res; 2019 Aug; 8(4):1137-1147. PubMed ID: 35116856
[TBL] [Abstract][Full Text] [Related]
2. Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data.
Guo G; Chen X; He W; Wang H; Wang Y; Hu P; Rong Y; Fan L; Xia L
PLoS One; 2018; 13(12):e0208547. PubMed ID: 30513126
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
[TBL] [Abstract][Full Text] [Related]
5. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
[TBL] [Abstract][Full Text] [Related]
6. Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy.
Manojlovic N; Savic G; Nikolic B; Rancic N
World J Clin Cases; 2022 Jan; 10(3):899-918. PubMed ID: 35127905
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy.
Jiang C; Liu S; He W; Zhang B; Xia L
J Cancer; 2017; 8(8):1410-1416. PubMed ID: 28638455
[No Abstract] [Full Text] [Related]
8. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer.
He W; Yin C; Guo G; Jiang C; Wang F; Qiu H; Chen X; Rong R; Zhang B; Xia L
Med Oncol; 2013 Mar; 30(1):439. PubMed ID: 23307251
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
10. [The value of NLR, FIB, CEA and CA19-9 in colorectal cancer].
Qian X; Wang H; Ren Z; Jin F; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Apr; 55(4):499-505. PubMed ID: 33858062
[No Abstract] [Full Text] [Related]
11. Change in the neutrophil-to-lymphocyte ratio during chemotherapy may predict prognosis in patients with advanced or metastatic colorectal cancer.
Nemoto T; Endo S; Isohata N; Takayanagi D; Nemoto D; Aizawa M; Utano K; Togashi K
Mol Clin Oncol; 2021 May; 14(5):107. PubMed ID: 33815795
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Passardi A; Azzali I; Bittoni A; Marisi G; Rebuzzi F; Molinari C; Bartolini G; Matteucci L; Sullo FG; Debonis SA; Gallio C; Monti M; Valgiusti M; Muratore M; Rapposelli IG; Ulivi P; Frassineti GL
Ther Adv Med Oncol; 2023; 15():17588359231212184. PubMed ID: 38107830
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy.
Shin K; Jung EK; Park SJ; Jeong S; Kim IH; Lee MA
World J Gastrointest Oncol; 2021 Aug; 13(8):915-928. PubMed ID: 34457195
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer.
Yamada Y; Sakamoto S; Rii J; Yamamoto S; Kamada S; Imamura Y; Nakamura K; Komiya A; Nakatsu H; Ichikawa T
Prostate; 2020 May; 80(7):559-569. PubMed ID: 32134137
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis.
Zhao N; Xu H; Zhou D; Xu X; Ge W; Cao D
J Gastrointest Oncol; 2022 Aug; 13(4):1772-1781. PubMed ID: 36092324
[TBL] [Abstract][Full Text] [Related]
16. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy.
Michl M; Koch J; Laubender RP; Modest DP; Giessen C; Schulz Ch; Heinemann V
Tumour Biol; 2014 Oct; 35(10):10121-7. PubMed ID: 25023402
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of related factors of prognosis after surgical treatment of patients with non-metastatic colorectal cancer and construction of a normagram prediction model].
Liu SX; Zhang L; Shi YK; Han XH
Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):167-172. PubMed ID: 35184461
[No Abstract] [Full Text] [Related]
19. Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and CEA as the Potential Prognostic Biomarkers for Colorectal Cancer.
Ming-Sheng F; Mei-Ling D; Xun-Quan C; Yuan-Xin H; Wei-Jie Z; Qin-Cong P
Can J Gastroenterol Hepatol; 2022; 2022():3109165. PubMed ID: 35028301
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy.
Asama H; Suzuki R; Takagi T; Sugimoto M; Konno N; Watanabe K; Nakamura J; Kikuchi H; Takasumi M; Sato Y; Irie H; Hikichi T; Ohira H
Mol Clin Oncol; 2018 Oct; 9(4):408-414. PubMed ID: 30233794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
